ライフサイエンスコーパス: dronabinol

1 nistered Delta(9)-tetrahydrocannabinol (THC; dronabinol).

2 availability and clearer dose-linearity than dronabinol.

3 given 1 dose of placebo or 2.5 mg or 5.0 mg dronabinol.

4 marijuana and -0.04 (CI, -0.20 to 0.14) for dronabinol.

5 s of marijuana (0.00, 1.98, or 3.56% THC) to dronabinol (0, 10, or 20 mg).

6 Hydromorphone+dronabinol 10 mg produced a high rate of dysphoric effec

7 morphone+dronabinol 5 mg and hydromorphone + dronabinol 10 mg produced AEs.

8 ent study shows minimal benefit of combining dronabinol (10 mg) and hydromorphone (4 mg) for analgesi

9 acebo, (2) hydromorphone (4 mg)-placebo; (3) dronabinol (10 mg)-placebo, and (4) hydromorphone (4 mg)

10 10 mg)-placebo, and (4) hydromorphone (4 mg)-dronabinol (10 mg).

11 algesia only improved in the hydromorphone + dronabinol 2.5 mg condition.

12 Overall, only hydromorphone+dronabinol 2.5 mg modestly enhanced hydromorphone-based

13 Hydromorphone + dronabinol 2.5 mg showed the lowest and hydromorphone+dr

14 g/d liquid suspension plus placebo, (2) oral dronabinol 2.5 mg twice a day plus placebo, or (3) both

15 of placebo, hydromorphone (4 mg; oral), and dronabinol (2.5 mg, 5.0 mg, 10 mg; oral).

16 Marijuana (1.98, 3.56%) and dronabinol (20 mg) also increased abuse-related subjecti

17 morphone-based analgesia and hydromorphone + dronabinol 5 mg and 10 mg increased risk for abuse and A

18 rate of dysphoric effects, and hydromorphone+dronabinol 5 mg and hydromorphone + dronabinol 10 mg pro

19 l 2.5 mg showed the lowest and hydromorphone+dronabinol 5 mg showed the highest risk for abuse.

20 We compared the effects of dronabinol, a nonselective agonist of the cannabinoid re

21 Dronabinol affected fasting distal MI in patients, regar

22 Dronabinol affected fasting proximal MI in patients with

23 se were not significantly increased over the dronabinol alone condition.

24 among advanced cancer patients compared with dronabinol alone.

25 lerance did not differ between marijuana and dronabinol, although dronabinol produced analgesia that

26 ent group, 329 received at least one dose of dronabinol and 164 received at least one dose of placebo

27 d Drug Administration-approved cannabinoids (dronabinol and nabilone), which include nausea and vomit

28 to (-)-Delta(9) tetrahydrocannabinol (THC) (dronabinol) and R,R-formoterol (arformoterol) illustrate

29 omorphone) and delta-9-tetrahydrocannabinol (dronabinol), as well as their effects on physical and co

30 In all patients, dronabinol decreased fasting proximal left colonic MI co

31 Compared with placebo, marijuana and dronabinol decreased pain sensitivity (3.56%; 20 mg), in

32 t under controlled conditions, marijuana and dronabinol decreased pain, with dronabinol producing lon

33 agonist, Delta(9)-tetrahydrocannabinol (THC; dronabinol), decreases marijuana withdrawal symptoms, ye

34 We investigated whether oral dronabinol (Delta(9)-tetrahydrocannabinol) might slow th

35 ydrocannabinol marijuana cigarette, a 2.5-mg dronabinol (delta-9-tetrahydrocannabinol) capsule, or a

36 Dronabinol did not alter sensation or tone.

37 s safety concerns (114 [35%] patients in the dronabinol group had at least one serious adverse event,

38 145 patients in the dronabinol group had EDSS score progression (0.24 first

39 -PHYS score was 0.62 points (SD 3.29) in the dronabinol group versus 1.03 points (3.74) in the placeb

40 ary end point (marijuana group, 20 patients; dronabinol group, 22 patients; and placebo group, 20 pat

41 Our results show that dronabinol has no overall effect on the progression of m

42 Dronabinol has poor bioavailability, which may contribut

43 when comparing prescribed cannabinoids (eg, dronabinol, nabilone) with placebo or active comparators

44 A consistent dose-effect relationship of dronabinol on hydromorphone across all measures was not

45 ents were randomly assigned (2:1) to receive dronabinol or placebo for 36 months; randomisation was b

46 ared with placebo (overall P = .05; for 5 mg dronabinol, P = .046), decreased fasting distal left col

47 gave an estimated between-group difference (dronabinol-placebo) of -0.9 points (95% CI -2.0 to 0.2).

48 r between marijuana and dronabinol, although dronabinol produced analgesia that was of a longer durat

49 rse events than placebo, but hydromorphone + dronabinol produced more moderate adverse events than bo

50 arijuana and dronabinol decreased pain, with dronabinol producing longer-lasting decreases in pain se

51 ients with IBS with diarrhea or alternating, dronabinol reduces fasting colonic motility; FAAH and CN

52 erage changes in viral load in marijuana and dronabinol relative to placebo were -15% (CI, -50% to 34

53 harmaceuticals, Somerset, NJ, USA), Marinol (dronabinol; THC; AbbVie, Inc., North Chicago, IL, USA),

54 te improvement and weight gain compared with dronabinol-treated patients: 75% versus 49% (P =.0001) f

55 of analgesic effects of smoked marijuana and dronabinol under well-controlled conditions using a vali

56 and oral delta-9-tetrahydrocannabinol (THC; dronabinol) using a within-subject, double-blind, random

57 le enhancement of hydromorphone analgesia by dronabinol was observed on evoked pain indices.

58 The effects of dronabinol were greatest in patients with IBS with diarr